Clinical trials: Lymphoid Neoplasms
Lymphoid Malignancies
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
- Trial name
- NCT01013818
- Testing
- HGS1029
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Human Genome Sciences Inc.
B-cell Malignancy, Marginal Zone Lymphoma
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion…
- Conditions
- B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- CaDAnCe-101 (NCT05006716)
- Testing
- Tacabrutideg
- Where
- 114 sites in United States, Australia and 14 more
- Volunteers
- 689 people
- Sponsor
- BeOne Medicines
B Cell Lymphoma, B Cell Leukemia
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
- Trial name
- NCT04156243
- Testing
- CD19 CARvac T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute…
- Trial name
- NCT04684147
- Testing
- single dose of CNCT19
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Juventas Cell Therapy Ltd.
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
Advanced Solid Tumors, Lymphoid Malignancies
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.
- Trial name
- NCT00529438
- Testing
- Bardoxolone methyl
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined…
- Trial name
- NCT06051409
- Testing
- Olverembatinib, Investigator's choice of TKI
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 350 people
- Sponsor
- Ascentage Pharma Group Inc.
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Lymphoma
Beta Alethine in Treating Patients With Low-Grade Lymphoma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00007839
- Testing
- beta alethine
- Where
- United States
- Sponsor
- LifeTime Pharmaceuticals
Leukemias, Acute Myeloid Leukemia (AML)
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous…
- Conditions
- Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL)
- Trial name
- NCT00664677
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Erimos Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one…
- Trial name
- BRUIN CLL-322 (NCT04965493)
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 176 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- Loxo Oncology, Inc.
All Conditions, All
Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort
To evaluate the reliability of using the iTremor device to accurately measure Ocular Microtremor (OMT) across a diverse cohort, representative of the US population, with a view to establishing this as a standard measurement tool…
- Trial name
- NCT07858214
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Head Diagnostics
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
- Trial name
- NCT01682616
- Testing
- ABT-199, Rituximab
- Where
- 6 sites in United States, Australia
- Volunteers
- 49 people
- Sponsor
- AbbVie
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Trial name
- NCT00088543
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 14 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Lymphocytic Leukemia
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).
- Trial name
- ASSURE (NCT04008706)
- Testing
- Acalabrutinib
- Where
- 108 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The primary purpose of this study is to evaluate the safety, toxicities, dosage and response rate for an investigational drug, motexafin gadolinium, administered to patients with chronic lymphocytic leukemia or small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma
- Trial name
- NCT00290004
- Testing
- motexafin gadolinium
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies.
- Trial name
- NCT01090414
- Testing
- Idelalisib
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a multi-center, open-label, dose escalation study.
- Trial name
- NCT01699152
- Testing
- TG02 citrate
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, CLL
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
- Trial name
- NCT00021749
- Testing
- Oblimerson sodium, G3139
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genta Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.